United-Guardian, Inc. — Q1 2024 10-Q Summary
Business context and reporting period
Quarter ended March 31, 2024; results are unaudited and compared with Q1 2023. United-Guardian manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. The specialty industrial product line was discontinued after Q2 2023.
Key financial results
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net sales | $3.255 million | $2.570 million |
| Gross profit / gross margin | $1.698 million / 52% | $1.477 million / 57% |
| Operating income | $1.027 million | $832,000 |
| Net income | $925,000 | $756,000 |
| Basic and diluted EPS | $0.20 | $0.16 |
| Cash from operations | $644,000 | $418,000 |
- Sales increased 27%. Cosmetic ingredient sales rose 146% to $1.876 million, largely due to higher purchases by distributor Ashland Specialty Ingredients (ASI). Pharmaceutical sales fell 30% to $950,000, principally reflecting lower Renacidin sales; medical lubricants were roughly flat.
- Gross margin declined to 52% from 57%, primarily because products sold in Q1 carried higher per-unit overhead costs following lower production in 2023. Operating expenses increased 10%; R&D expense decreased 19%.
- Investment income was $98,000, up from $48,000; net gains on marketable securities were $41,000, down from $73,000. The company had repositioned investments toward U.S. Treasury bills.
- Cash and cash equivalents were $7.073 million and marketable securities were $1.536 million at March 31. Working capital was $10.568 million, with a 6.7:1 current ratio. Cash declined $1.170 million during the quarter, including $1.148 million of dividends paid.
- Total liabilities were $1.882 million; the filing reports no borrowings or debt. Net cash from investing activities was negative $665,000, mainly reflecting purchases of marketable securities. Capital expenditures were $22,000.
Material changes and management commentary
- ASI purchases of cosmetic ingredients increased 227% year over year. Management attributes the increase to stronger Lubrajel demand, particularly in China, and customers replenishing inventory after working through excess stock.
- Renacidin production was disrupted by a temporary shutdown at the contract manufacturer in Q4 2023. Sales remained allocated until March 2024, when supplies were sufficient to fill orders. The filing says Renacidin is made by one contract manufacturer.
- The company declared and paid a $0.25-per-share dividend in February 2024. It expects to consider dividends semiannually in January and July.
Outlook, risks and other items
- No sales or earnings guidance is provided. Management expects a 21% effective tax rate for fiscal 2024 and believes working capital will support operations for at least the next 12 months.
- The company anticipates beginning production and reporting sales of its Natrajel sexual wellness ingredient line in 2024; no sales were reported in 2023.
- Management warns that Red Sea/Suez disruption could cause longer raw-material lead times and higher shipping costs, potentially affecting gross margins. The company had not yet experienced those effects as of the filing.
- Other risks include softer consumer demand, higher interest rates, lower-priced competitors, customer and supplier concentration, and reliance on the single Renacidin contract manufacturer. Four distributors accounted for 83% of gross sales and 90% of receivables in Q1 2024.
- A building sprinkler-system upgrade was underway: $99,000 incurred to date, with an additional $69,000 expected in 2024; completion was expected in Q2. The filing reports no legal proceedings, and no separate risk factors were listed in Part II.
- CMS approved the company as a “specified small manufacturer” for the Medicare Part D discount program, providing a phase-in of the new discounts expected to begin in 2025. The ultimate financial effect remains uncertain.
Important facts for investors to verify
- Whether the sharp increase in ASI orders reflects durable end-market demand or temporary customer inventory replenishment, particularly given China exposure.
- Renacidin production continuity and the contract manufacturer’s ability to meet demand after the prior shutdown.
- Whether higher production volumes improve unit overhead and gross margin, which fell five percentage points year over year.
- The timing and commercial traction of Natrajel, and the financial impact of the Medicare Part D discount changes after the phase-in.
- Customer and raw-material supplier concentration, along with any emerging effects from shipping disruptions, inflation, or weaker consumer demand.